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AGREEMENT BETWEEN SELF-REPORT AND 
 
URINE DRUG TEST RESULTS IN A SAMPLE OF PATIENTS 
 
TREATED WITH BUPRENORPHINE FOR OPIOID USE DISORDER 
 




Background: Urine drug testing (UDT) is recommended to monitor primary care 
patients treated for opioid use disorder with buprenorphine. Whether UDT data 
contributes clinically useful information beyond patient self-report of drug use has 
received minimal attention. It is unclear whether differences between patient self-
report and UDT results varies with time in treatment.   
Objectives: To estimate concordance between self-report and UDT results and 
evaluate if discordant results are associated with time in treatment.  
Methods: Retrospective review of electronic medical records of patients enrolled 
in the Office Based Opioid Treatment program at Boston Medical Center 
between January 2011–April 2013. Typically, patients submit a urine sample for 
UDT at the beginning of a clinical visit and are subsequently asked about recent 
cocaine and opioid use which is documented in the electronic medical record. 
We compared UDT results to patient self-report of cocaine and opioid use.  
Results: Of 1,755 UDT from 130 patients, 4% (78/1755) were positive for 
cocaine and 10% (157/1563) for opioids other than buprenorphine. At visits with 
a cocaine positive UDT, 76% of patients (59/78) did not disclose cocaine use. At 
visits with an opioid positive UDT, 57% of patients (89/157) did not disclose 
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opioid use. The odds of having a positive UDT for either cocaine or opioids with 
no disclosure of use decreased over a year of treatment. 
Conclusion: In a sample of primary care patients with opioid use disorder 
treated with buprenorphine, fewer than 10% of UDTs were positive for cocaine or 
opioids, and in these instances patient self-reported use of cocaine or opioids 
less than half the time. As duration of treatment increased, patients were more 
likely to disclose use.  Urine drug testing contributes new and useful information 
for clinical consideration of the optimal care of patients with drug use disorders; 
how best to collect and utilize this information merits further study. 
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Background 
Drug testing can be used as a tool for primary prevention, diagnosis and 
monitoring of patients at risk of a substance use disorder (SUD) or with a 
diagnosed SUD. Although drug testing can identify recent exposure to drugs, it 
cannot be used to diagnose a SUD outside of the clinical context. For patients 
treated with buprenorphine for an opioid use disorder (OUD), urine drug testing 
(UDT) is a routine part of monitoring and treatment in the USA but this is not the 
recommended practice in some other countries (e.g., United Kingdom).  
Federal organizations including Substance Abuse Mental Health Services 
Administration (SAMHSA) and professional groups such as American Society for 
Addiction Medicine (ASAM) have published guidelines and consensus 
statements about the use of urine drug testing in addiction treatment.1,2 The 
treatment guidelines for buprenorphine outlined by SAMHSA TIP #40 
recommend that UDT be checked at least monthly once a patient is in the 
maintenance phase of treatment.1 In a White Paper published in 2014, The 
American Society for Addiction Medicine (ASAM) called for “smarter” drug 
testing. They advocate for increased random testing, improved sample collection, 
increased technology to decrease adulteration or substitution of urine, and 
consideration of financial costs when ordering tests. More recently, ASAM 
released a consensus statement named the “Appropriate Use of Drug Testing in 
Clinical Addiction Medicine”.2 This statement includes both clinical 
recommendations for drug testing in clinical addiction medicine and also 
  2 
identified gaps in the research. These gaps include the process and frequency of 
drug testing in addiction treatment and duration of testing.  
In general clinic practice, providers typically ask about recent substance use in 
addition to using UDTs. However, in the addiction treatment literature, the 
available evidence about self-report of drug use suggests variability in reliability 
in this method.3–8 Many of the studies that have examined self-report of drug use 
in comparison to UDT results have occurred in tightly controlled clinical trials and 
do not provide practical, observational information about the clinical effectiveness 
of UDT.4,7,8 In addition, the objective of those studies is often to determine if self-
report is a valid measure. The studies have not determined the optimal frequency 
of UDT or tried to understand the continued use of UDT when patients are 
engaged and successful in treatment.  
In the studies that have been conducted in observational conditions, both under-
reporting and over-reporting has been reported.5,6 It has been hypothesized that 
patients may over-report if they are trying to enter treatment but then under-
report later in treatment if they are worried about being discharged from the 
program. These studies rarely provide information about whether there are 
certain characteristics of individuals that may indicate a need for increased 
testing or identify groups of patients for whom testing is not needed.  
In one clinical trial of individuals with a prescription OUD treated with 
buprenorphine, UDT results were consistent with self-report 87.3% of the time. 
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Those who reported initially using opioids for pain with a positive UDT for opioids 
were more likely to deny opioid use when asked. The two groups did not differ in 
terms of treatment outcomes.8  
Despite the paucity of data to guide clinical practice, determining whether there is 
ongoing cocaine and opioid use during treatment with buprenorphine may have 
implications for treatment success.9,10 Clinically, providers worry that ongoing 
substance use may be a reflection that medication treatment may not be effective 
and that individual may need increased treatment. Although studies have 
demonstrated that people with OUD who also use cocaine can be successfully 
treated with buprenorphine, baseline and ongoing cocaine use is associated with 
worse treatment outcomes in patients treated with buprenorphine. It is possible 
that ongoing opioid use may indicate that that the effective buprenorphine dose 
has not been achieved. As a therapeutic relationship develops between patients 
and prescribers over time, disclosure of cocaine and opioid use may increase. 
Whether UDT results provide clinically useful information about cocaine or opioid 
use beyond self-report for patients treated with buprenorphine in office-based 
settings is not known. In other words, is there a benefit in testing patients beyond 
what can be learned from asking them about recent use during in a clinical visit? 
One consideration about UDT collection processes is that collecting the UDT 
prior to asking patients to self-report likely enhances the accuracy of self-report 
(aka “truth-telling”). Thus, the act of giving a urine sample may be a motivation to 
disclose use — in other words the UDT is an intervention.  
  4 
Despite this barrier, in order to begin to address the gaps in the literature, the 
objectives of this study were to 1) determine the frequency of non-disclosure of 
opioid and cocaine use among patients with opioid use disorder treated with 
buprenorphine and 2) evaluate if non-disclosure of opioid and cocaine use is 
associated with time in treatment.  
Methods 
Subjects and Setting 
This was a retrospective electronic medical record review of patients in the Office 
Based Opioid Treatment program (OBOT) at Boston Medical Center between 
January 2011 and December 2013. OBOT is an urban, academic program that 
relies on a collaborative care model between nurse care managers (NCM) and 
generalist physicians who are waivered to prescribe buprenorphine in an office-
based setting.11 All data were originally entered into the electronic medical record 
for patient care purposes. Data was extracted from the electronic medical 
records of patients treated with buprenorphine in OBOT.12  
Urine Drug Testing 
Patients in the OBOT program are routinely screened for buprenorphine, 
oxycodone, methadone, amphetamines, barbiturates, cocaine, opiates, and 
benzodiazepines. Every time a urine toxicology screen is ordered, a NCM 
documents patient self-reported substance use that same day. Toxicology is 
initially checked weekly, then biweekly and less frequently as the patient 
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becomes more stable in treatment. 
Inclusion 
1. ≥ 18 years of age 
2. Patient started buprenorphine treatment in the Office Based Opioid Treatment 
Program at Boston Medical Center between January 2011 and December 2013 
with at least one prescription for buprenorphine.  
Exclusion 
1. Patients seen in OBOT but never received a prescription for buprenorphine.  
2. Patient in OBOT but is treated with naltrexone.  
Outcome Measures:  
The primary dependent variable is unacknowledged UDT result (yes vs. no) for 
opioids or cocaine. An opioid positive UDT was defined as one positive for 
oxycodone, methadone, or opiates (i.e., morphine, codeine). A cocaine positive 
UDT was defined as one positive for cocaine. Per protocol, UDT is conducted 
weekly, then biweekly and less frequently as the patient becomes stable.  UDTs 
are sent to the laboratory at our institution and are immunoassays. There are 
times that confirmation tests are requested by providers and gas chromatography 
mass spectrometry (GCMS) is available through a send-out mechanism but this 
is unusual. Typically, a nurse or medical assistant collects an unobserved urine 
sample for UDT from the patient prior to the patient visit. Every time a UDT is 
ordered, a nurse care manager (NCM) documents on that same day the patient’s 
self-reported use. In order to categorize patients as disclosing use or denying 
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use, we abstracted the text from each note associated with a UDT. We then 
electronically searched the notes to categorize them as “discloses use” or 
“denies use”. Notes that contained a denial of use were categorized as “denies 
use”. The specific terms sought were: denies use, denies any use, denies drug 
use, denies substance use, denies drug or alcohol use, denies drug or alcohol 
use, denies any recent use, denies all drug/etoh use, denies all use, denies drug 
and etoh use, and denies all drug and etoh use. The remainder were sent to the 
first author (SMB) for review and categorization. To ensure fidelity, we manually 
reviewed a random sample of nursing notes that were categorized by code.  
Based on date, we matched each UDT result with a nursing note for a specific 
time point. 
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Definitions of Variables 
Variable Name Definition 
UDT positive 
Any UDT result with the following characteristics: positive for 
opiate (not on medication list), oxycodone (not on medication 
list), cocaine, barbiturate (not on medication list), 
benzodiazepine (not on medication list), or stimulant (not on 
medication list) OR buprenorphine negative 
UDT negative 
Any UDT result that is negative for all substances except 
buprenorphine (or benzodiazepine or amphetamines or 









Disclosure of use in OBOT nursing note + UDT positive for 




Denial of use in OBOT nursing note + Negative for opiates, 
oxycodone, cocaine, benzodiazepine, amphetamines, 




Disclosure of use in OBOT nursing note + Negative for 
opiates, oxycodone, cocaine, benzodiazepines, 
amphetamines, barbiturates AND positive for buprenorphine  
 
Covariates: All data were collected from the electronic medical record.  
• Gender (male, female) 
• Race (White, Black/African American, Hispanic/Latino, Asian, Other) 
• HIV status (problem list) 
• Hepatitis C status (problem list) 
• Psychiatric diagnoses 
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Statistical Analysis 
Aim One: Estimate the proportion and frequencies of unexpected, discrepant 
UDT (patient report negative/UDT positive events) by duration of treatment.   
Analysis: To address the first aim, we categorized patients based on UDT results 
and disclosure of use. We created 5 categories of time in treatment: 1–30 days, 
31–90 days, 91–180 days, 181–365 days and greater than 365 days.  Within 
each time period, if patients had at least one UDT result positive for opioids and 
did not disclose use for that UDT, we categorized them as “Opioid use not 
disclosed to nurse” for that time period.  If patients disclosed use for all UDT 
results (whether positive or negative) during the time period, we categorized 
them as “Opioid use disclosed to nurse.”  If patients had only negative UDT 
results and never disclosed use during the time point, we categorized them as 
“No opioid use by UDT or self-report.”  We repeated this categorization scheme 
for cocaine. 
Each patient could only contribute one observations to each time period. We 
excluded UDTs that were positive for opioids if the patient had a prescription for 
an opioid in the prior 30 days despite what the positive result was. It is possible 
that a prescription could have been filled outside of our medical system but it was 
not possible to have collected that information.  
 
Aim Two: Evaluate whether duration in treatment is associated with patient 
report negative/ UDT positive events. 
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Hypothesis: Those with shorter time in treatment have greater odds of having 
patient report NEG/UDT POS than other subjects. 
Outcome: Patient report NEG/UDT POS for cocaine and opioids 
Independent variables: 1–12 months in treatment 
Analysis:  
For the second aim, to account for clustering due to multiple UDT results per 
patient, generalized estimating equations (GEE) logistic regression models were 
fit to evaluate whether duration in treatment is associated with patient report 
negative/ UDT positive for cocaine or opioids. Our hypothesis was that those with 
shorter time in treatment would have greater odds of having patient report 
negative/UDT positive compared to those in treatment for greater than 1 year. 
We considered time in treatment as the independent variable and the dependent 
variable as a patient report negative/UDT positive result for opioids or cocaine. 
We used an independence working correlation and reported results using 
empirical standard errors. In the adjusted model, we controlled for age at start of 
treatment, gender, race/ethnicity, hepatitis C diagnosis and any history of a 
psychiatric diagnosis.  
Results 
3.1 Sample Description  
We identified 209 patients with a start date of buprenorphine between 1/1/2011 
to 4/30/2013. Of those 209 patients, we identified 130 patients with a first 
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prescription during the study period that had a corresponding UDT and nurse 
note. (See Figure 1 for more detail). These patients had a total of 1755 visits 
(mean=13.5 visits/per patient) during the study period. Baseline characteristics 
are shown in Table 1.  
 
3.2 Self-Report of Opioid and Cocaine Use Compared to UDT  
We excluded 9 patients with 192 UDTs who had a past 30-day prescription for an 
opioid that could have explained the positive results. Of the remaining 1563 
UDTs, results were positive for opioids in 157 (10%). At 57% (89/157) of the 
visits when there was an opioid positive UDT and no corresponding opioid 
prescription from our electronic medical record, patients did not disclose opioid 
use at the nursing visit.  
 
UDTs were positive for cocaine 4% (78/1755) of the time. At 76% (59/78) of the 
visits when there was a cocaine positive UDT, patients did not disclose cocaine 
use at the nursing visit. About 25% of all patients had a UDT that was positive for 
cocaine during the study period. 
 
3.3 Self-Report of Opioid and Cocaine Use Compared to UDT Results by Time in 
Treatment 
As time in treatment increased, the proportion of individuals who did not disclose 
opioid use, but had a UDT positive for an opioid decreased. (Table 2) As time in 
treatment increased, the proportion of individuals who did not disclose cocaine 
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use, but had a UDT positive for cocaine decreased until one year. (Table 3) 
 
3.4 Time as a predictor of Opioid or Cocaine Positive UDTs with no disclosure 
The odds of having an opioid UDT without disclosing use were significantly 
higher for UDTs taken during the first 6 months compared to after one year. 
(Table 4) A similar result was observed for cocaine although the results were 
only statistically significant for those in treatment less than 90 days compared to 
those in treatment for > 1 year (Table 5). 
Discussion 
In this study of 130 patients treated with buprenorphine who provided 1755 
UDTs, both cocaine and opioid positive UDTs were uncommon (4% and 10% 
respectively) overall. However, patients did not disclose their substance use for 
76% of the UDTs positive for cocaine and 57% of the UDTs positive for opioids. 
Having a positive UDT for either cocaine or opioids with no disclosure of use was 
more common early in treatment.  
UDT is routinely performed because of the assumption that the data collected are 
more useful than what a clinician can gather by interview alone (i.e., self-report).  
However, little data exist to make a case that UDT is better than simply using 
self-report. In the context of the need for smarter use of health care dollars, it is 
important the health care providers understand the value of tests that they order. 
There is agreement among providers and professional organizations that UDT 
has a role in the primary care delivery of buprenorphine for patients with OUD as 
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it reveals undisclosed periods of drug use or supplements patient self-report of 
drug use and provide an opportunity for earlier intervention to bolster recovery.  
This work adds to the body of literature suggesting that UDTs are a useful 
adjunct to patient self-report to identify substance use in patients. There are 
various reasons that patient self-report will not be sufficient that have been 
described elsewhere. For example, patients may have concerns about being 
discharged from treatment if they disclose use or they may feel shame about 
relapse and do not want to disappoint their care team.13,14 Prior studies have 
focused on individuals treated with methadone or who are in clinical trials. This 
study adds to the literature by focusing on patients with OUD treated with 
buprenorphine. As there is an increasing shift of providing OUD treatment in 
primary care settings, understanding the role of UDT will become increasingly 
important.  
We found that as patients are in treatment for a longer amount of time, that their 
opioid and cocaine use decreases. The current guidelines recommend less 
frequent testing as patients become stable in their recovery.1 Those guidelines 
have been based on expert consensus and importantly this study provides 
evidence to support that practice. This is key because as noted in the recent 
consensus statement, research is lacking in this field. This finding suggests that 
patients may be more willing to disclose use as they are in treatment longer 
possibly due to having an opportunity to develop a trusting relationship with their 
clinical team. The other possibility is that some patients will continue to use and 
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abstinence may take longer to achieve. For those patients, continued monitoring 
may be beneficial. Patients with substance use disorder experience stigma in the 
health care setting and it may therefore take time to develop a trusting 
relationship with providers as suggested by this study.  
A main limitation of this study is potential misclassification of denial or disclosure 
of use. We attempted to assess the magnitude of such error by manually 
reviewing a random sample of nursing notes that were categorized by code. 
Although we found that the electronic coding matched the manual review, it is 
possible that notes were randomly misclassified. As UDTs were collected as part 
of clinical care, there was variation in how often UDTs were collected. The UDTs 
were based on immunoassay results which have include the possibility of false 
positive UDT results given the specificity of these assays. An additional limitation 
is that over time the number of patients in the sample decreased as they dropped 
out of care. It is possible that the odds of a positive UDT with no disclosure of 
use decreased because it was a sample of patients who were overall more 
stable. Finally, as this is a study of a clinical program with different NCMs 
assessing substance use, there could be variation in how NCMs perform.  
The strengths of this study include using a large, clinic based sample with clinical 
data. As the value of UDT in clinical setting is a relatively unexplored field, using 
data initially collected for clinical purposes and not research is a strength 
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because it allows us to see in a practical way how UDT results can be used and 
interpreted.  
Conclusions 
In conclusion, although tests positive for opioids or cocaine are uncommon for 
people in treatment, when tests are positive they are not consistent with self-
report. The inconsistency between UDTs and self-report is reduced over time. 
further study should elucidate optimal UDT protocols that take into account the 
overall infrequency of unexpected UDTs and the trend for less revelation of 
undisclosed drug use as time in treatment advances.  Determining the optimal 
use of information gained from both UDT and substance use self-report can help 
improve the chronic care of patients with opioid use disorders in primary care. 
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Figure 1. Eligibility of patients in OBAT for study comparing urine drug test 




209 patients between 1/1/2011 
and 4/30/2013 
Excluded:  
4 patients with no visit data 
 
11 patients with no treatment plan data 
 
12 patients with no visit data and 
treatment plan data on the same date 
 
3 patients on naltrexone 
 
48 patients who first visit within their first 
stint was >30 days after start of first stint 
 
1 patient with no visit during first t stint 
 
130 patients with UDT results 
and NCM visit data for analysis  
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Table 1: Baseline Characteristics of Patients with an Opioid Use Disorder in an 
Office Based Opioid Treatment Program receiving Buprenorphine, N=130 (1755 
associated Urine Drug Tests) 
 
Variable % (N) 
Age (years, median, range) 41 (22–61) 
Gender (female) 33.1% (43) 
Unemployed 63.9% (83) 
Race/ethnicity 
   White 
   Hispanic 
   Black/African American 






Hepatitis C (positive antibody) 34.6% (45) 
History of psychiatric diagnosis 75.4% (98) 
Any UDT positive for cocaine during the study period 30.0% (39) 
Any UDT positive for a non-prescribed opioid during 
the study period 50.8% (66) 
Follow-up time (days, median (range)) 297 (4–1166) 
Discontinued care during follow-up period 50.8% (66) 
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Table 2: Proportion of Patients in OBOT with UDT results positive or negative for 
opioids and disclosure to nurse about use by time in treatment (N=121)* 
 
















Initial UDT 121 13.2% (16) 15.7% (19) 71.1% (86) 
Last UDT before discontinuation in 
the observation period 121 14.1% (17) 8.3% (10) 77.7% (94) 
1–30 121 19.8% (24)  16.5% (20)  63.6% (77)  
31–90 100 20% (20)  10% (10)  70% (70)  
91–180 63 12.7% (8)  17.5% (11) 69.6% (44)  
181–365 45 15.6% (7) 8.9% (4)  75.6% (34)  
>365 days 23 8.7% (2) 4.3% (1) 87% (20) 
 
* 9 were excluded for having an opioid prescription within the 30 days prior to the 
positive UDT  
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Table 3: Proportion of individuals with UDT results positive or negative for 
cocaine and disclosure to nurse about use by time in treatment (N=130) 
 





use to nurse 
%(N) 





disclosure to RN 
%(N) 
Initial UDT 130 10.0% (13) 3.1% (4) 86.9% (113) 
Last UDT before 
discontinuation in the 
observation period 
130 6.2% (8) 1.5% (2) 92.3% (120) 
1–30 130 13.1% (17)  3.8% (5)  83.1% (108)  
31–90 109 11.9% (13)  1.8% (2)  86.2% (94)  
91–180 71 12.7% (9)  0  87.3% (62)  
181–365 50 8% (4) 4% (2)  88% (44)  
>365 27 14.8% (4)  0  85.2% (23)  
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Table 4: Time in treatment as a predictor of opioid or cocaine positive UDT with 






Time in Treatment  Opioid Positive 
UDT/No Disclosure of 
Use  
OR (95% CI) 
Cocaine Positive 
UDT/No 
Disclosure of Use  
OR (95% CI) 
Days 1–30  7.25 (1.91, 27.6) 5.16 (1.81, 14.71) 
Days 31–90  5.01 (1.32, 18.95) 3.02 (1.10, 8.25) 
Days 91–180  3.34 (1.05, 10.61) 2.28 (0.83, 6.24) 
Days 181–365  3.21 (0.73, 14.03) 0.88 (0.30, 2.57) 
>365 days 1.00 (reference) 1.00 (reference) 
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